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Purpose: Options for leveraging available teleme-
dicine technologies, ranging from simple webcams and
telephones to smartphone apps and medical-grade
wearable sensors, are evolving faster than the culture
of clinical research. Until recently, most clinical trials
relied on paper-based processes and technology. This
cost- and labor-intensive system, while slowly chang-
ing, remains an obstacle to new drug development.
Alternatives that use existing tools and processes for
collecting real-world data in home settings warrant
closer examination.
Methods: The site-less clinical research organiza-
tion (CRO) model, whereby pharmacists or other
health care professionals provide useful and timely
counseling for protocol compliance by regular phone
and videoconferencing sessions, is a flexible approach
to managing clinical trial participants directly from
their homes. An expert panel, including clinical
specialists in metabolic or neurodegenerative diseases,
health information technology and CRO innovators,
and the pharmaceutical industry, met in Dallas, Texas,
December 2016, to discuss advancing avenues for site-
less CRO and other remote clinical trial practices,
taking into account investigator, sponsor, and regu-
latory perspectives.
Findings: Real-time “site-less” management of clin-
ical trials can augment traditional research and devel-
opment methods by providing data from a broader,
more diverse group of patients in real-world practice
settings. This methodology also helps to proactively
identify safety profile and operational issues. Current
use of site-less CRO practices constitutes an important] 2017bridge to alternative trial models, including “large
simple trials” that strive to answer one or two
questions using data derived from representative
patient populations treated in typical clinical settings.
Implications: Site-less CROs offer a working
example of how remote technologies and in-home
monitoring methods can address shortcomings of
conventional drug development. This model maxi-
mizes time and cost, as well as potentially earlier
identification of adverse events. Coordinated commu-
nication among investigators, sponsors, regulators,
and patients will be needed to develop standardized
strategies for incorporating site-less CROs into current
and future study design. (Clin Ther. 2017;]:]]]–]]])
& 2017 The Authors. Published by Elsevier HS
Journals, Inc.
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less.BACKGROUND
In 2011, Pfizer conducted the first clinical trial of a US
Food and Drug Administration (FDA)-approved phar-
maceutical, using Web- and smartphone-based tech-
nologies to recruit and manage participants entirely
from their homes. Called REMOTE (Research
On Electronic Monitoring of Overactive Bladder1
Clinical TherapeuticsTreatment Experience), this feasibility study was
initiated in response to an increasingly challenging
drug development environment marked by rising
costs, lengthening cycle times, escalating levels of
protocol complexity, and a dynamic regulatory envi-
ronment.1 Despite early termination of the REMOTE
trial (described below), lessons learned about the
strengths and weaknesses of its specific Web-based
components have stimulated interest in the potential
of technology-driven clinical trial methodologies
to complement conventional methods of drug
development.
The need for such innovation is well documented.
According to the Tufts Center for the Study of Drug
Development, bringing a new therapeutic entity
through research and development (R&D) takes at
least 10 years, and the average capitalized cost,
factoring in the shared cost of compounds that fail,
exceeds US$2.6 billion.2,3 The period of clinical test-
ing is particularly time- and cost-intensive, with site
monitoring alone comprising between 9% and 14%
of overall expenditures.4 Uncertainties of recruitment
and retention pose additional, ever-present risk. An
estimated 11% of sites in any multicenter global
clinical trial fail to enroll a patient, almost 40% fail
to meet initial recruitment targets, and 49% of
all enrolled participants drop out before study
completion.2,5
Perennial barriers to recruitment and retention are
lack of proximity to academic medical centers, where
trials are usually conducted, and the inability (or
unwillingness) of participants to commit to multiple
follow-up visits.6 Inefficient trial management and the
demand for larger and more diverse sample sizes over
wider geographic areas, to determine whether a drug
is well tolerated and efficacious across all age groups
and ethnicities, are additional hurdles.7THE EVOLUTION OF SITE-LESS CLINICAL
TRIALS
The aforementioned Phase IV REMOTE trial was
considered groundbreaking in its objective to validate
the use of Web-based methodologies in clinical re-
search. The efficacy and tolerability of the active
treatment (tolterodine tartrate extended release) had
been previously found in site-based trials, thus allow-
ing comparison with results derived from Web-based
methodologies. The protocol received endorsement2from two institutional review boards and the US
FDA.1,8 After viewing the introductory webpage,
candidates could opt to create an account, which
began the screening process. Of 20,901 individuals
who viewed the study’s introductory webpage, 17,950
watched an online informational video, more than
7000 people completed the account registration page,
and more than 5000 re-confirmed their e-mail ad-
dress. However, each step was associated with a loss
of potential participants.
Ultimately, 118 participants proved eligible for the
study under informed consent, but only 18 were
randomly assigned to treatment. Sharp dropouts
occurred at two points: the multiple-stepped online
identity verification procedure and the placebo run-in
period when participants were asked to enter bladder
e-diary data on a sponsor-supplied mobile phone.
Investigators observed that processes and equipment
could have been simpler and more user-friendly at
both junctures. Aspects that worked well were the
interactive online consent and the shipment of the
study drug directly to patients.1
In 2015, the “virtual” trial concept was reinforced
when the US FDA solicited feedback on the use of
telehealth technologies to improve efficiency of clinical
trial conduct.9 Major drug companies in Europe and
the United States launched feasibility trials using Web-
based methods. The European trial, sponsored by
Sanofi, assessed the utility of a 3G-enabled wireless
blood glucose meter for glucose profiling from remote
sites.10 Participants registered themselves by a clinical
research cloud platform, reviewed patient information
electronically, signed informed consent electronically,
and received other study materials directly at home.
Coordination of the study required 66% less time
compared with a conventional site-based study using a
similar protocol, and compliance improved 18%.11
In the United States, Genentech incorporated a
videoconferencing and messaging platform into a
trial of treatment for a rare autoimmune skin
condition occurring in less than 1/100 of 1% of the
global population.12 Candidates from seven US states
were recruited through the “virtual” site, and
enrollment was more than 20 times faster than that
projected for non-remote sites.
In keeping with this movement, the first “site-less”
clinical research organization (CRO) was set up by
the organization of one of the current authors.13,14
Described in more detail below, it uses certifiedVolume ] Number ]
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real-time participant data and to engage with people
in their homes. CTRPs are specially trained, licensed
pharmacists with expertise in clinical trials, medication
issues, and patient counseling, to educate and commu-
nicate with patients. To date, CTRP services have
supported more than 5000 patients in 27 studies.13
With the number of devices connected to the
Internet projected to exceed 20 billion by 2020,
mobile health technologies are evolving exponen-
tially—faster than the culture of clinical research.15,16
Collecting clinical trial real-world data in a home
setting can give sponsors and study managers visibility
and assurance around Good Clinical Practice in ways
that were not previously possible. The remainder of
this article offers an overview of the landscape and a
broad framework for aligning site-less CRO goals and
processes with regulatory standards. The framework
synthesizes investigator, sponsor, CRO, and regula-
tory perspectives gleaned from a roundtable discus-
sion held in Dallas, Texas, December 3, 2016. The
core goals are to improve patient access to clinical
trials, streamline clinical research operations for all
stakeholders, and enhance access to more good
quality medicine for more patients.
Roundtable participants included clinical specialists
in metabolic or neurodegenerative diseases, health
information technology and CRO innovators, and a
representative from the pharmaceutical industry. This
forum was viewed as a first step in establishing
coordinated communication among investigators,
sponsors, and regulators to develop standardized
strategies for incorporating site-less CRO methods
into drug (and device) development. Future meetings
will build on the observations presented below.CURRENT EXAMPLES AND PURPOSES
Unlike site-based clinical trials that require regular
visits to a designated research facility, site-less clinical
trials are conducted in participants’ homes by a
central virtual coordinating center (hereafter referred
to as a site-less CRO). Site-less CROs use video-
conferencing and other telehealth technologies to
conduct trial activities such as recruitment, screening,
informed consent, education, and data collection.17
Direct communication and relationships between
participants and a trusted study health professional
are key features. The model is evolving rapidly in] 2017tandem with numerous telehealth platforms and can
be paired with traditional clinical research processes,
depending on study design. At the most basic level,
site-less CROs deliver efficiency benefits, such as real-
time data edit-checks, enhanced data verification and
processing, and improved workflow and protocol
compliance.
More broadly, as the following examples suggest,
site-less CRO “visits”—implemented through syn-
chronous (same time) or asynchronous (different time)
communication platforms—can potentially increase
engagement, extend geographic reach, and reduce
variability in assessments.18 They are ideally used
when (1) no office visits/assessments are required or
remote assessments are appropriate, (2) participants
live in disparate or remote geographic areas, (3)
participants have complex diseases or other issues
that make site visits difficult (eg, those with disabilities
or who need to be accompanied), (4) cold-chain
medicines must be transported, and/or (5) study
duration is long.
Situations in which site-less CRO methods are not
appropriate in other than hybrid studies (ie, those
integrating site-based and site-less practices) include
the necessity of a “loading intravenous dose,” multiple
dosing using a health care team member, an uncertain
safety profile and/or disease state, and reliance on
medical imaging techniques (eg, magnetic resonance
imaging).
Finally, site-less CROs also provide medical monitor-
ing, adverse event alerts, scale and safety assessments, and
insights into patient-reported outcomes.19 Enhanced
ability to chart the natural history of intractable disea-
ses, such as genetic, neurodegenerative, or metabolic
conditions, is another potential contribution.
Parkinson Disease: Web-Based
Videoconferencing
The Fox Trial Finder is an online clinical trial-
matching tool that encourages individuals with
Parkinson disease and their caregivers to participate
in clinical research.20 Drawing from its database of
more than 42,500 individuals, researchers solicited
volunteers from throughout the United States to use
videoconferencing from their homes in an effort to (1)
demonstrate the feasibility of virtual research visits
within this population, (2) collect phenotypic data of
the participants, (3) validate self-reported diagnosis,
and (4) gauge interest in virtual research visits.3
Clinical TherapeuticsAfter providing informed consent by telephone, inter-
ested individuals (n ¼ 204) were e-mailed a baseline
survey. Those who completed the survey were sent a
link to download secure videoconferencing software
onto their desktop, laptop, or tablet computer. During
the virtual visit, participants completed paper-based
cognitive assessment tasks, captured through screen
shots, and a neurologist conducted visual assessments.
Of 166 virtual research visits, neurologists judged
Parkinson disease as the most likely diagnosis in
97% of cases, validating self-reported diagnosis and
adding to the phenotypic data already in the Fox Trial
Finder registry.
A sister study used videoconferencing to evaluate
50 people who had undergone direct-to-consumer
genetic testing for Parkinson disease.21 The main
objective was to determine the level of agreement
between individuals’ self-reported data and the remote
observations of a neurologist. Although self-reported
diagnosis, age of onset, and family history were highly
congruent with the neurologist’s assessment, agree-
ment was lower for subjective symptoms, such as the
presence of falling, tremor, and lightheadedness.
Researchers hope that these studies will set the stage
for cost-efficient larger scale trials that can target
genetic subpopulations of different disorders.
Alzheimer Disease: Continuous In-Home
Monitoring for Mild Cognitive Impairment
The use of home studies for early detection of
cognitive decline in older adults is noteworthy because
accumulation of amyloid beta protein, a precursor to
frank Alzheimer disease, is not readily detected with
conventional clinical assessment approaches.22 In
addition, Alzheimer disease drug candidates have
one of the highest failure rates of any disease area.23
Home assessment provides the opportunity to discern
relevant measures of real-world function (eg, daily
medication adherence, conversational interactions,
speech characteristics, or sleep measures) that are
not surrogate markers, but rather patient-centered
outcomes in their own right. Home-based studies also
facilitate research involving caregivers as a proxy to
provide information about the participant-subject or
to enable research focusing specifically on caregiver-
centered issues.
The Oregon Center for Aging and Technology
(ORCATECH) offers a far-reaching prototype. Re-
searchers installed a system of strategically placed4sensors in more than 480 homes and have been
collecting data for approximately 8 years. The system
measures gait and mobility, sleep and activity pat-
terns, medication adherence, and computer use.24–26
Accurate tracking of such activities in patients with
cognitive impairment and refining techniques for
detecting motor and cognitive changes are key aims
of the program. One of the largest challenges has been
differentiation of residents. This problem may be
addressed by requiring the participants to wear or
carry a radio frequency identification tag. Methods
that eliminate the need for additional equipment
or hardware are under development.25 As is, the
ORCATECH approach has been received favorably
by study participants, with a withdrawal rate of only
2.6% per year. Moreover, 23 of 24 participants who
moved to a new home during the study chose to have
the system reinstalled.27
Diabetes: CV Outcomes Trials and Pharmacist-
Led Site-Less CROs
Since 2008, glucose-lowering diabetes drug R&D
has been heavily focused on a US FDA guidance to
the pharmaceutical industry that specifies enhanced
requirements before and after approval for demonst-
ration of cardiovascular (CV) tolerability.28 To date,
17 prospective, randomized, controlled clinical trials
involving more than 140,000 participants have been
completed or are ongoing as the result of this
guidance. The studies randomize a large number of
people with type 2 diabetes and high CV risk to prove
non-inferiority for major cardiovascular events. The
sheer number of people needed to accrue the required
number of CV events in limited time has provided an
unprecedented opportunity to observe risks and bene-
fits of type 2 diabetes drugs even beyond CV out-
comes.29 Indeed, the gliptin (dipeptidyl peptidase-4
inhibitor) studies Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (n ¼ 14,671), Saxagliptin
Assessment of Vascular Outcomes Recorded in Pa-
tients with Diabetes Mellitus—Thrombolysis in My-
ocardial Infarction 53 (n¼16,492), and Examination
of Cardiovascular Outcomes with Alogliptin versus
Standard of Care (n¼5380) have already provided
useful insights into pancreatic, renal, fracture, and
cancer risk.30–32 At the same time, these studies
highlight the operational and technical challenges of
international multicenter trials.33 Common challenges
include differences in technology infrastructure,Volume ] Number ]
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collection, cost structures, language, definitions of
adverse events, and country-specific clinical practice
and ethical perspectives.
Large, simple trials (LSTs) that efficiently address one
or two clinically meaningful outcomes are a proposed
solution. LSTs have long been used for regulatory
purposes and are embraced by the US FDA.33,34 In
general, they are characterized by large sample sizes,
less-restrictive entry criteria, streamlined data collection
requirements, and objectively measured or adjudicated
end points. In addition, they may be conducted across
real-world health care settings. Thousands of patients or
“sites,” including investigators with little or no previous
trial experience, may be registered through the Internet,
social media, or e-mail. Infrastructure supports include
centralized monitoring and electronic data capture.34 By
harnessing vast reservoirs of clinical practice data,
conclusions can be reached in time to address pressing
health care needs and to ensure relevancy to the intendedSite-less CRO
Pharmacists facilitate recruitment, informed consent, enrollm
understanding, and regulatory compliance:
Enhances patient adherence to protocol
Reduces patient withdrawal
Reduces trial costs and time
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Figure 1. Site-less CRO. The site-less CRO (clinical resear
clinical trial research pharmacists (CTRPs) and
other telemedicine technologies. CTRPs collect
to assess patient safety and data quality. Th
sources with 24/7 support by e-mail and t
combined with legacy models as required (h
robust data quality and enhances patient com
] 2017population. In addition, LSTs can be applied to small,
even orphan-sized, populations as long as a few
objectively determined outcomes are assessed. Site-less
trials—large or small—can complement highly monitored
Phase III trials and reduce the time and cost of Phase III
programs for the entire spectrum of therapeutic
development.
A specialized CRO that uses an inter-operational
technology platform for centralizing clinical trial processes
represents a step toward bringing the LST concept to full
fruition. The site-less CRO strives to assess interventions
in representative care settings and, as previously men-
tioned, relies on CTRPs to provide useful and timely
counseling for safe medication use and protocol compli-
ance (Figure 1).13 Although specific methodologies vary
with protocol requirements, recruitment and screening
may be accomplished through pharmacies and
pharmacists. Previous studies in the community and
inpatient settings have found the positive impact
pharmacists can have on medication adherence, adverseent, protocol 
Pharmacist Coordination: Technology/Phone/Video Conferencing
Legacy Model and Patient Office Visits: Site/Physical
e visit at baseline and end of study according to protocol
ch organization) model builds relationships between
study participants by audio, videoconferencing, and
and review all data as they are reported in real-time
ey also provide study participants and review data
elephone. This centralized model, which may be
ybrid model design), facilitates patient safety and
pliance practices that support study completion.
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Clinical Therapeuticsevents, and costs.35,36 In addition, pharmacists have been
used in large randomized usual-care studies to dispense
and monitor medications.37 Pharmacists are uniquely
qualified to identify and address medication-related prob-
lems proactively, given their training in drug dosing and
interactions, time intervals for administration, and proper
storage and use of medications and devices. Maximizing
this expertise in clinical research has been shown to help
participants follow prescribed protocols and to reduce
costly adverse events.13,38
A recent composite analysis of interventions made
by CTRPs in 12 diabetes drug trials suggests that
pharmacist counseling produces comparable benefit in
the research setting.39 In these trials of non-insulin
glucose-lowering drugs administered by injection, an
intervention was defined as a patient report or answer
to a pharmacist question in which the pharmacist
corrected or intervened to prevent errors and protocol
violations. Participants were contacted by telephone at
predetermined critical trial junctures, and, in most
trials, pharmacists were available 24 hours a day, 7
days a week to address questions or concerns.
Overall, the majority of patients (92.3%) had at least
one intervention over the course of multiple calls, and of
these interventions 55% were classified as “high-impact”
pertaining to concurrent medications, medication usage,
and events that would materially impact compliance and
the primary end point of the trial. Because adverse events
are often related to poor medication adherence and
retention issues, this pharmacist-led site-less CRO model,
by supporting positive medication-taking practices, en-
courages continued study participation with implicit
economic and therapeutic benefit.38
Moreover, depending on the context, site-less CRO
studies may require minimum to no visits with the
patient’s health care provider. Although this approach is
still in its infancy, the simultaneous evolution of LSTs,
medical-grade wearable sensors that can measure critical
physiological indicators, and demand by patient advo-
cates, professional consortia, and regulatory agencies for
end points that take patients’ experience into account,
portends its rapid growth.40–42 Future studies will eval-
uate how well site-less CRO methodologies translate to
cost-effectiveness for the sponsor.FRAMEWORK FOR ACTION
The vision of how Web-based communication tech-
nologies may be harnessed to enhance clinical research6and evidence-based practice is still unfolding. The
aforementioned examples illustrate that some loca-
tion- and platform-agnostic tools exist today and that
pathways for gathering and analyzing real-time data
are becoming more clearly defined. In addition, the
advent of site-less clinical trials offers many possibil-
ities for realizing more efficient research methods as
advocated in a recent editorial by US FDA authorities,
Robert Califf and Rachel Sherman, and Centers for
Medicare and Medicaid Services Acting Administra-
tor, Andrew Slavitt.42 The editorial, published in
JAMA, calls for three achievable changes to the
clinical trial process: (1) the enrollment of a more
diverse trial participant population and the
measurement of more relevant clinical outcomes, (2)
the development of links across different systems to
better capitalize on existing digital sources of
information to generate higher quality data at lower
cost, and (3) the collaboration of multiple stake-
holders across the public and private sectors.
A growing number of public–private partnerships
are working together to advance collaborative frame-
works for propelling this transition. Learning from
such organizations, as those listed below, may help
not only to shape strategies for adoption of site-less
CRO models in drug development but also to cultivate
champions who influence institutional change.
The Patient-Centered Outcomes Research Institute
(PCORI) is part of a developing infrastructure to
enhance study methods and to build capacity for
more efficient drug development.43 In 2016, PCORI
joined with the Centers for Disease Control and
Prevention, and the US National Institute of
Diabetes and Digestive and Kidney Diseases of the
National Institutes of Health to launch the Natural
Experiments Network dedicated to rigorous empirical
examination of large-scale, population-targeted health
policies and interventions for diabetes.44 Because
nearly 10% of Americans have diagnosed or
undiagnosed diabetes and the disease is largely self-
managed, this space is considered rife with
opportunity for tracking real-time or near real-time
health measures remotely.45
The nonprofit Critical Path Institute offers another
venue for concrete action among multiple stakehold-
ers, including industry, regulatory authorities, govern-
ment, patient advocacy groups, and academia.46 In
particular, its Electronic Patient-Reported Outcome
(ePRO) Consortium provides a pre-competitiveVolume ] Number ]
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industry, and academia are tasked to generate meas-
urement equivalence data, develop specification docu-
ments and data standards, and provide guidance on
methodologic considerations related to ePRO appli-
cations.47 Its best practice documents are available
through https://c-path.org/programs/epro/.
The International Conference on Harmonization of
Technical Requirements for the Registration of Phar-
maceuticals for Human Use (ICH) could be a strong
ally in advancing efforts to harmonize technical,
regulatory, and nomenclature issues about the use of
site-less clinical trials and CROs.48 To date, the ICH
has produced more than 45 guidelines describing
technical requirements related to the drug
registration process. The scientific level of each
guideline reflects state-of-the-art technology. Carefully
designed, implemented, and documented requirements
for site-less CRO processes, especially as related to
patients enrolled in many different countries, will
shape their routine use in clinical research.
The Clinical Trials Transformation Initiative
(CTTI) was co-founded in 2007 by Duke University
and the US FDA to address inefficiencies in clinical
trials.49 Informed consent and recruitment and use of
institutional review boards are among the broad range
of trial-related critical design and operational issues
covered in CTTI consensus-driven recommendations.
CTTI is implementing several projects to identify and
address challenges related to planning for and con-
ducting clinical trials that use mobile technology.50
Near- and long-term action items that could stim-
ulate a cycle of progress and improvement as site-less
CRO methodologies evolve entail identifying and
addressing operational efficiencies in drug develop-
ment, re-considering relevant outcomes and data
quality, working with patients to define patient-
centric end points, and improving the usability of
human-computer interfaces.51 In addition, prompt
identification of “low-hanging fruit,” such as
remote-e-consenting and direct-to-patient supply ship-
ments, will help the research community ride out the
economic and organizational challenges of initial
adoption.
A key unresolved issue is the lack of clear regu-
latory guidance addressing different components of
the site-less CRO prototype. A reflection paper from
the European Medicines Agency on risk-based quality
management in clinical trials and a 2013 guidance] 2017from the US FDA both embrace the use of centralized
monitoring systems incorporating new technolo-
gies.52,53 Previously, FDA issued regulations to estab-
lish the requirements under which the agency accepts
electronic records and electronic signatures. This
regulation, Title 21, Part 11 of the Code of Federal
Regulations and subsequent related guidance papers
represent continuing efforts to ensure that information
submitted to the agency is verifiable and accurately
represents original source data, even when collected
electronically.54–58 In Europe, Section 5.5 of the Note
for Guidance on Good Clinical Practice describes
requirements for the use of electronic trial data
handling and/or remote electronic data systems.59
A synthesis of preliminary goals, processes, and
regulatory considerations for site-less CROs based
on current Good Clinical Practice is presented in
Table I. It is hoped that this manageable focus will
suggest a definite path toward a new paradigm for
drug development.CONCLUSIONS
Both the high cost and long duration of drug develop-
ment—due in large part to the challenges of screening,
recruiting, enrolling, monitoring, and retaining pa-
tients in clinical trials—impede access to promising
treatments and cures for disease. Although the
randomized clinical trial remains the gold standard
for generating robust medical evidence, patients of
varying ages, races, and ethnicities, with concomitant
comorbidities and treatments, may not be represented.
When a clinical trial shows marked differences in
results among countries, for example, it may be
necessary to substantiate the generalizability of results.
To this end, real-time, centralized management of
clinical trials—optimally combining platform-agnostic
instruments for patient-centric real-time data capture
with site-less CRO capabilities—can augment tradi-
tional R&D methods by providing data from a
broader, more diverse group of patients in real-
world practice settings. The real-time aspect of site-
less CRO monitoring also helps to proactively identify
safety profile and operational issues and to increase
understanding of treatment-response interactions ear-
lier in the product life cycle. It is hoped that the
examples and observations provided in this article will
provide an impetus for the formalization of site-less
CRO processes. Progress in this area may potentially7
Table I. Aligning site-less CRO goals and processes with regulatory standards48,52–59.
High-Level Goals for
Site-Less CRO
Methodologies
Current Processes for
Incorporating Site-Less CROs
into Clinical Trials
Regulatory Standards to
Date
Need for Regulatory
Clarification
Enhance operational
efficiencies of drug
development (eg,
reducing burden on
participants, and
facilitating
participation by
individuals across
wide geographic
areas).
Use on-line methods that
enable prospective
participants to self-screen
(optional).
Computerized systems
should meet all regulatory
requirements with the
same confidence as that
provided with paper
systems.
Clarify policies and
lexicon about the use
of centralized
monitoring systems
and real-time data.
Use videoconferencing and
other electronic processes
with an interactive interface
to obtain informed consent
and to facilitate the
participant’s ability to
retain and understand
information (optional).
Appropriate controls should
be used to ensure that e-
records/dataand electronic
signatures are trustworthy,
accurate, and complete;
implement time stamps
with a clear understanding
of time zone references.
Clarify requirements for
validation of
individuals with
disease and data
arising from them.
Connect participants remotely
with subjects synchronously
(eg, by telephone,
videoconferencing) and/or
asynchronously (eg, by
texting, Web-based
platforms) for all issues,
including adverse event
reporting and inquiries
about the study.
Electronic consent may use
an interactive interface
(eg, multimedia, quizzes)
but requires systems to
ensure person signing in is
the subject and responses
cannot be altered.
Define appropriate
national and
international
regulatory bodies and
study coordination
procedures for trials
centrally managed by
site-less CROs.
Collect data directly from
participants through
pharmacist-led site-less
CRO counseling and
provide real-time
notifications of adverse
events.
Standard operating
procedures for
computerized systems
should provide
documentation for system
setup/installation; system
operating manual;
validation and
functionality testing; data
collection and handling;
system maintenance;
system security measures;
change control; data
backup and recovery
plans; alternative
recording methods;
computer use training;
relevant roles and
Address issues about
distributing drugs
across state lines and
the need for licensure
of investigators.
(continued)
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Table I. (continued).
High-Level Goals for
Site-Less CRO
Methodologies
Current Processes for
Incorporating Site-Less CROs
into Clinical Trials
Regulatory Standards to
Date
Need for Regulatory
Clarification
responsibilities of
sponsors, CROs, and
other parties using
computerized systems.
Enhance data quality Each study protocol should
identify each step at which
a computerized system will
be used to create, modify,
maintain, archive, retrieve,
or transmit source data.
Electronic source data and
source documentation
must meet the same data
quality criteria expected of
paper-based records (eg,
accurate, legible,
contemporaneous,
original, attributable,
complete, consistent,
enduring, available when
needed).
Clarify approval
requirements for tools
required for electronic
data capture and
transmission.
Clarify standards for
collection of
subjective data, such
as hypoglycemia and
social functioning.
Structured (eg, clinical and
health outcomes) and/or
unstructured (eg, patient-
and caregiver-reported
outcomes) data should be
collected during the
research process to
generate a broader
understanding of treatment
benefit in terms of how
patients feel and/or
function.
Appropriate controls (eg,
secure, computer-
generated, time-stamped
audit trails) are
fundamental to ensure the
protection of clinical data.
and ability to reconstruct
study activities.
Establish a credibility checklist
covering (1) informed
consent, (2) integrity of
randomization, (3)
confirmation of adequate
drug exposure, (4) reliable
event ascertainment, (5)
tolerability and adverse
event adjudication, (6) 21
CFR Part 11 compliance,
and (7) verification of key
source documents.
Enhance credibility of
results
Ensure unbiased and typically
double-blinded
randomization.
FDA and ICH guidance on
GCP (E6), general trial
design (E8), biostatistics
Develop specific FDA
and/or ICH guidance
(continued)
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Table I. (continued).
High-Level Goals for
Site-Less CRO
Methodologies
Current Processes for
Incorporating Site-Less CROs
into Clinical Trials
Regulatory Standards to
Date
Need for Regulatory
Clarification
(E9), and multiregional
clinical trials (E17).
on sparse data clinical
trials.
Use an appropriate
comparator (placebo or
active control).
Select the relevant patient
population.
Support innovative R&D
paradigms using
technology-driven
site-less CRO
methods
Forge public–private
collaborations with
stakeholders, including
patients, to determine how
site-less CRO models might
drive new research agendas,
streamline clinical trial
processes, and flesh out
clinically meaningful
end points (eg, biomarkers,
surrogate end points, and/or
PROs).
Risk-based monitoring,
including the appropriate
use of centralized
monitoring and reliance
on technological advances
(eg, e-mail, webcasts,
online training modules)
can meet statutory and
regulatory requirements
under appropriate
circumstances.
Define criteria for
support and
endorsement of
feasibility studies of
innovative approaches
to clinical trials.
CRO = clinical research organization; FDA = Food and Drug Administration; ICH = International Conference on
Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use; GCP = Good Clinical
Practice; PRO = patient-reported outcome; R&D = research and development; 21 CRF Part II = Title 21, Part 11 of the Code
of Federal Regulations.
Clinical Therapeuticscontribute to greater drug development output and,
more important, help the multitude of patients waiting
for new and innovative cures and therapies.ACKNOWLEDGMENTS
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